



# CDRH Top Priorities in 2000

---

David W. Feigl, Jr., M.D., M.P.H.


Director

Center for Devices and Radiological Health

# Overview

- ▶ Organization and Changes in the Device Program
  - CDRH
  - New England District
- ▶ FDAMA
- ▶ Regulations
- ▶ Reengineering
- ▶ Cross-cutting Activities
- ▶ Resources
- ▶ Alternatives in 510(k)s, MDRs
- ▶ Harmonization
- ▶ Hot Topics

# Center for Devices and Radiological Health



# Ombudsman

- ▶ Application closed 12-10-99
- ▶ Reports directly to the  
Center Director
- ▶ Outreach
- ▶ Follow-up
- ▶ Quality Systems  
on disputes and  
common problem  
areas

# Appeals Scorecard ---510(k)

81 appeals received as of January 1993

- ▶ 44 decisions upheld
- ▶ 31 decisions overturned
- ▶ 2 appeals have been withdrawn
- ▶ 4 appeals are pending

# Office of Device Evaluation

## Structure

- ▶ Current: 350 employees  
organized into 6 product review Divisions
- ▶ ODE will remain a single Office.
- ▶ Three Deputies:
  - Deputy Director for Science and Regulatory Policy (Phil Phillips)
  - Deputy Director for Clinical and Review Policy I (Kimber Richter)
  - Deputy Director for Clinical and Review Policy II (new)
- ▶ Office Director applications due by mid-February 2000.
- ▶ Search Committee chaired by Li Joseph.

# New England District

- ▶ This district includes Massachusetts, Maine, New Hampshire, Vermont, Connecticut and Rhode Island.
- ▶ District office with a staff of 97 is located in Stoneham, Massachusetts.
- ▶ >6800 companies with  
36% of these medical devices and radiological health products

# New England District

---

- ▶ New England's medical device industry consists of 465 Class II and III device firms - second only to Los Angeles' 640 firms.
- ▶ The Bay State resident post is located in Worcester where 11% of device firms are located.
- ▶ The Boston Area is home to 35% of device firms.

# Massachusetts

## Medical Device Applications (CY'99)

- ▶ 23 original IDE applications
- ▶ 2 original PMA applications
- ▶ 43 PMA supplements
- ▶ 261 510(k) applications  
(3 reviewed by third party)
  - 216 traditional
  - 34 special
  - 11 abbreviated

# Massachusetts Device Firms Registered with CDRH in 1999

- ▶ 2,056 total companies registered
  - Includes out-of-business, tentatively closed, temporary registration via 510(k) entry, and not-required-to-register
- ▶ 695 companies registered as active status
  - District has assigned registration number
- ▶ 18 companies registered as pending status
  - District to inspect firm and make determination

# Massachusetts Inspections 1999

## FDA-conducted inspections:

- ▶ 102 medical device firms covering 155 products
- ▶ Mammography Inspections
  - 2 VA hospitals and
  - 4 audit inspections under the Mammography Quality Standards Act
  - 206 inspections completed by the State
- ▶ 34 X-ray field tests inspections
- ▶ 1 inspection of a laser facility

# MDR Reports from Massachusetts Manufacturers 1999

## ▶ Top five reported products:

- 640 (25%) -- low energy defibrillators
- 401 (15%) -- automatic, external defibrillators
- 372 (14%) -- intraaortic balloon system
- 92 ( 4%) -- arthroscope and accessories
- 88 ( 3%) -- intravascular filters

# Warning Letters (CY'99)

- ▶ In CY'99, five device warning letters were issued, two referencing design control problems.
- ▶ Two firms were involved in the device warning letter pilot program.
- ▶ Warning letters were averted based on adequate, timely responses to FDA-483s.

**FDAMA**

# Themes of FDA Modernization Act

- ▶ Interactive process for product review
- ▶ Decisive action
- ▶ Patient access
- ▶ Codifies reengineering
- ▶ Agency discretion, not mandatory requirements
- ▶ FDA review accountability/timeliness

# FDAMA Accomplishments

- ▶ Completed
  - 24 guidance documents and
  - 6 final rules
- ▶ Recognized
  - >400 consensus standards
- ▶ Exempted
  - more than 60 Class II devices
- ▶ Approved
  - 13 third parties for 510(k) reviews
- ▶ Designated
  - >150 device types for 3rd party review

# FDAMA Accomplishments

- ▶ Piloted
  - Sentinel postmarket reporting
- ▶ Instituted
  - interactive “determination” and “agreement” meetings with sponsors
- ▶ Rescinded
  - 55 tracking orders
- ▶ Chartering
  - advisory panel for scientific disputes
- ▶ Expanded
  - stakeholder participation through open meetings nationwide

# Regulations Published in '99

62 regulations published in CY '99 so far

- ▶ 7 final rules
- ▶ 3 Direct to Final Rules
- ▶ 11 Proposed Rules
- ▶ 38 Notices
- ▶ 3 Advanced Notice of Public Rule Making (ANPR)

# Reengineering Implementation In 1999

## Phase I

GMP-HACCP-OC

BIMO-OC

Rad Health-OC

Postmarket-OSB

## Phase II

Registration and Listing -  
OC

Hazard Benefit

Information Dissemination

## Phase III

510(k) - ODE

IDE/PMA - ODE

PDP Process - ODE

515(b) - ODE

Standards - OST

Regulations - OHIP

Recall - OC

GMP - QSIT - OC

MDR - OSB

# Reengineering

## Examples of Reengineered Processes

- ▶ New 510(k) paradigm
- ▶ Regulations development
- ▶ Recalls
- ▶ GMP inspections
- ▶ Products development protocol (PDP)
- ▶ Modular PMA review
- ▶ Standards


# Reengineering

## New Projects

- ▶ Postmarket process
- ▶ Registration and listing
- ▶ QSIT and HACCP
- ▶ Class I recalls
- ▶ Radiological health
- ▶ Bioresearch monitoring

# Device GMP Inspections

## FY 93 - FY 98



# Inspections: How to get more from decreasing \$\$\$?

Changes are allowing Field to make best use of its time and resources in device inspections:

- ▶ “Grassroots” changes
- ▶ Reengineering changes
  - QSIT : Quality System Inspection Technique
  - HAACP: Hazard Analysis and Critical Control Points

# Inspections:

## “Grassroots” Changes

- ▶ Pre-announced inspections
- ▶ Annotation of 483's
  - Company corrections
- ▶ Post-inspection letters to all  
*vs.* only Warning Letters
- ▶ Warning Letters
  - 15 days to respond to 483's
  - Untitled letter if response satisfactory

# QS IT:

## Quality System Inspection Technique

- ▶ Paradigm shift: looking at systems rather than at product problems
- ▶ Inspection focuses on four subsystems
  - Management controls
  - Design controls
  - Corrective and preventive action (CAPA)
  - Production and process controls

# HACCP: Hazard Analysis and Critical Control Points

- Goal: to prevent production problems
- Inspectional approach: mfrs. determine their critical control points, control them
- Investigators and auditors focus on critical control points

# 510(k)s - Alternatives

	Applications Received (4-98 to 9-99)	Review Complete	Average Review Time
Abbreviated	105	82	91
Special	458	411	28
Traditional	6147	6453	110

# 510(k)s - Third party review

- ▶ 154 device types eligible
  - mostly class II
- ▶ same device types = 1200 510(k)s / yr
- ▶ only 32 510(k)s submitted to 3rd parties so far this fiscal year
- ▶ Average total review time for comparable 510(k)s -- same product code & fiscal year:
  - 3rd party - 57 days
  - All FDA review - 105 days


# Summary Reporting of MDRs

Goal: Reduce "noise" in the MDR system, improve the signal to noise ratio

- ▶ Allow periodic submission of well-known, repetitive reports in line item format
- ▶ Expect 38,000 summary reports in FY '99
- ▶ 45 manufacturers participating
- ▶ 52 exemptions
- ▶ New system in place for January 2000

# Manufacturer Reports

(Includes Summary Reporting)



# What's Driving CDRH to Reengineer its Program Processes and Financial Management Practices?


- ▶ Resource erosion from 4 years of flat dollar budgets
- ▶ Performance improvements in device review bought at the expense of other programs
- ▶ Resource demands of FDAMA implementation
- ▶ Rising payroll costs make operating budget below acceptable minimum



# CDRH FTE History

Fiscal Years 1976 - 1999\*

- Mammography Act
- Radiological Health
- Medical Devices




Med. Dev. Amend.

Merger of BRH & BMD


SMDA MQSA

FDAMA


# Flat Budget = Declining Staff



# CDRH FTE Distribution



**FY95**  
**N=1,109**



**FY98**  
**N=1,037**

# Appropriations for FY 2000

- ▶ Bill signed Oct. 22, 1999
- ▶ Allocates \$114 M to CDRH & \$40 M to field for CDRH activities, mandating:
  - Use of \$1 million for reprocessed devices -- premarket review, enforcement, oversight
  - Allocation of no less than \$55.5 million and 522 FTEs by whole agency for premarket review to meet statutory timeframes
  - Reauthorization of mammography user fees

# Impact of FY 2000 Appropriations

- ▶ Center and Field must absorb 4.8% pay raise and other inflationary costs
- ▶ \$7M increase for device review results in reductions in other areas due to absorbing inflationary costs
- ▶ \$1M mandate on reuse of devices must come from base resources; not funded

# Global Harmonization

Four study groups:

- ▶ Regulatory Requirements / Premarket Review
- ▶ Device Vigilance / Post-Market Surveillance
- ▶ Quality System Requirements and Guidance
- ▶ Auditing

# Global Harmonization



8th meeting in September 2000  
Hosted by Canada

[Http://www.ghtf.org/default.htm](http://www.ghtf.org/default.htm)

# U.S. / EU MRA

## What it is:

- ▶ Surrogate Inspector and Reviewer
- ▶ EU must learn U.S. system and implement it like U.S.
- ▶ U.S. must learn EU system and implement it like EU

## What it is not:

- ▶ Not acceptance of CE mark
- ▶ Not harmonization
- ▶ Not equivalence of U.S. and EU systems



# Hot Topics

# Reuse

FDA's policy is changing because:

- ▶ Types of single-use devices being reprocessed
- ▶ FDA laboratory findings
- ▶ Widespread practice but little data on safety or effectiveness
- ▶ Single-use labels not clearly meaningful
- ▶ Single-use labels don't identify vulnerabilities
- ▶ Patients are not informed -- experimentation?

# Tissue-based Products

## Concern about transmissible spongiform encephalopathies (TSE)

- ▶ Dura mater and Creutzfeldt-Jakob Disease
  - 1987 cases of transmission of CJD to donor
  - FDA requirements for processing human dura mater
- ▶ FDA meetings to address issues, increase knowledge
- ▶ International Workshop on Clearance of TSE Agents from Blood Products and Implanted Tissues

# Fetal Ultrasound Monitors

"Keepsake" videos of the fetus.

- ▶ Ultrasound is a Class II prescription medical device.
- ▶ A letter to manufacturers in 1994 explained that fetal ultrasound for souvenir purposes is not approved and is an unnecessary exposure to radiation.
- ▶ FDA is aware of about 10 locations per year where keepsake ultrasound videotaping occurs.
- ▶ One seizure occurred in 1997.
- ▶ This is a cottage industry involving registered sonographers and becomes a practice of medicine issue.

# People Scanners

People scanners are not medical devices but are handled strictly as radiological products.

- ▶ These products screen people for contraband and weapons and are used primarily in prisons and some international airports.
- ▶ The issue of exposure to ionizing radiation for nonmedical purposes is monitored by CDRH.
- ▶ At the annual meeting of the Technical Electronic Product Radiation Safety Standards Committee (TEPRSSC) recently, recommendations made there in 1998 were further discussed.

# Year 2000



<http://www.fda.gov/cdrh/yr2000/year2000.html>

# CDRH: The Future

---

Transparent

Adequately Resourced

Re-engineered

FDAMA-ed

Science Based

Partners

Credibility